Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Stroke Characteristics in Post-Stroke Epilepsy Cohort: A Single Center Experience
Cerebrovascular Disease and Interventional Neurology
P15 - Poster Session 15 (12:00 PM-1:00 PM)
4-011

Characterize the stroke subtype, location, and demographic features of patients with post-stroke epilepsy in a single center experience. 
Post-stroke epilepsy (PSE) is a common complication of stroke. At least 10% of stroke patients develop PSE within five years of their stroke. PSE is thought to be caused by the increase of intracellular Ca2+ and Na+ with a resultant lower threshold for depolarization, glutamate excitotoxicity, hypoxia, metabolic dysfunction, global hypoperfusion, or hyper-perfusion injury. PSE is a well-known complication that affects stroke outcomes; however, the specific stroke subtypes that have a higher prevalence of PSE remain unknown. 

We performed a retrospective review of electronic medical records at the University of Utah and queried charts of patients with a diagnosis of stroke and epilepsy who were also evaluated on at least one occasion by a Neurologist between January 2000 to October 2019. 

We identified over 2000 unique patients with a possible diagnosis of PSE. The average age was 68.5±18.1 years (range from 19 to 97), with 53% male. We will describe their stroke subtypes including TOAST classification, location of the stroke, parent artery of stroke, post-stroke medical management, admission National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale, as well as other demographic and clinical data. 
Over 10% of ischemic stroke patients are diagnosed with PSE within five years of their stroke. We are performing chart review of this cohort to provide a detailed characterization of stroke subtypes associated with an increased risk for PSE which may potentially help neurologists to predict the risk of PSE and, in a second stage, the most appropriate treatment in PSE.   
Authors/Disclosures
Ka-Ho Wong (U of U Neurology Clinic)
PRESENTER 		The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Cecilia Peterson An immediate family member of Ms. Peterson has received personal compensation for serving as an employee of 100Plus.
Lilly Fagatele (University of Utah Neurology) Ms. fagatele has nothing to disclose.
No disclosure on file
Amir M. Arain, MD, FÂ鶹´«Ã½Ó³»­ (University of Utah) Dr. Arain has nothing to disclose.
Blake Newman, MD (University of Utah) Dr. Newman has nothing to disclose.
Adam De Havenon, MD, FÂ鶹´«Ã½Ó³»­ (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.